
Overview
Healthcare real estate REIT's Q4 net income and EPS beat analysts' expectations
Company capitalizing on private market demand with $1 bln asset sales plan
Outlook
Healthpeak sees 2026 diluted EPS between $0.34 and $0.38
Company expects 2026 Nareit FFO per share of $1.70 to $1.74
Result Drivers
CAPITAL RECYCLING - Healthpeak is selling stabilized assets to reinvest in high-growth opportunities, including life science campuses
TECHNOLOGY INNOVATION - Healthpeak is focusing on automation and data initiatives to improve performance
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 EPS | Beat | $0.16 | $0.06 (6 Analysts) |
Q4 Net Income | Beat | $113.85 mln | $66.91 mln (4 Analysts) |
Q4 Adjusted FFO |
| $331.71 mln |
|
Q4 FFO |
| $333.11 mln |
|
Q4 Adjusted FFO Per Share |
| $0.40 |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 10 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the specialized reits peer group is "buy"
Wall Street's median 12-month price target for Healthpeak Properties Inc is $19.00, about 10.2% above its January 30 closing price of $17.24
The stock recently traded at 66 times the next 12-month earnings vs. a P/E of 68 three months ago
Press Release: ID:nBw5nb8lPa
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.